Bumetanide Shortage: What Providers and Prescribers Need to Know in 2026

Bumetanide supply disruptions that emerged in 2025 created significant management challenges for cardiologists, nephrologists, internists, and primary care providers whose patients depend on this loop diuretic for daily edema management. This guide summarizes what prescribers need to know in 2026: the scope of the shortage, evidence-based substitution strategies, dose conversion tables, and tools to help patients locate available supply.

Shortage Overview: What Was (and Is) Affected

Confirmed supply disruptions in mid-2025 primarily affected:

Bumetanide 1 mg oral tablets: Manufacturing issues caused confirmed shortages through at least August 2025, confirmed by the Department of Health and Social Care (DHSC) and multiple US distributors.

Bumetanide injectable (0.25 mg/mL): Multiple manufacturers including Novadoz reported shortages of specific injection strengths in August–September 2025; Fresenius Kabi and Hikma maintained partial supply.

Note: IV loop diuretic shortages are not a new phenomenon — bumetanide injection was part of a broader IV loop diuretic shortage identified by the SCCM in January 2021.

As of 2026, the oral tablet supply has largely improved, but regional and formulation-specific variability persists. Providers should verify availability before prescribing new courses of bumetanide for new patients.

Pharmacology Refresher: Why Bumetanide Is Not Interchangeable 1:1

Bumetanide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, with a potency approximately 40 to 60 times greater than furosemide on a milligram-for-milligram basis. Its oral bioavailability is 80–95%, compared to furosemide's highly variable 10–100%. This superior and consistent bioavailability is often the clinical reason bumetanide is preferred over furosemide — particularly in patients with gut edema, heart failure with reduced absorption, or chronic kidney disease.

Loop Diuretic Dose Equivalency Table

Use the following approximate equivalencies when substituting. Note that individual patient response may vary, especially in CKD patients, and close clinical monitoring is required after any transition:

1 mg bumetanide (oral/IV) ≈ 40 mg furosemide (oral) ≈ 20 mg furosemide (IV) ≈ 10–20 mg torsemide (oral/IV)

2 mg bumetanide ≈ 80 mg furosemide (oral) ≈ 40 mg furosemide (IV) ≈ 20–40 mg torsemide

3 mg bumetanide ≈ 120 mg furosemide (oral) — note: higher bumetanide doses may require greater proportional furosemide doses; monitor closely

Substitution Strategy by Patient Profile

Patients on bumetanide due to furosemide allergy:

Furosemide is contraindicated. Consider torsemide (same sulfonamide structure as bumetanide and furosemide, but cross-reactivity is generally low) or ethacrynic acid (Edecrin) for confirmed sulfonamide hypersensitivity. Prioritize remaining bumetanide supply for these patients.

Heart failure patients stable on bumetanide:

Furosemide at an equivalent dose is the most practical substitution. However, given furosemide's variable oral bioavailability, patients may require closer monitoring and dose titration. Torsemide is an evidence-supported alternative with better bioavailability and once-daily convenience. Weigh the practical stocking situation (furosemide is virtually always available) against the clinical ideal.

CKD patients with furosemide-resistant edema:

These patients were often switched to bumetanide specifically because of its superior oral bioavailability in CKD. Switching back to furosemide may result in inadequate diuresis. Torsemide may be a better alternative in this population; consider specialist consultation.

38,083+ patients found their medications in stock

38K+

Find Bumetanide In Stock Today →

Key Monitoring Parameters During Any Diuretic Transition

Daily weight (instruct patients to weigh each morning, report gain >2 lbs in 1 day or >5 lbs in 1 week)

Serum electrolytes (K+, Mg2+, Na+) and BUN/creatinine within 1–2 weeks of any dose or agent change

Signs and symptoms of hypovolemia: dizziness, orthostatic hypotension, decreased urine output

Signs of inadequate diuresis: peripheral edema, dyspnea on exertion, orthopnea, worsening JVD

A Tool to Help Your Patients Find Bumetanide

When bumetanide is available but patients simply can't locate it at their pharmacy, medfinder for providers gives you a resource to direct patients to. medfinder calls pharmacies near the patient to check which ones have their specific medication in stock and texts them the results — reducing unnecessary substitutions and emergency calls to your office.

See our full provider guide to helping patients find Bumetanide in stock for actionable workflow integration tips.